NASDAQ$IMCR
Immunocore Holdings plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Immunocore's financial position and operational performance for Q1 2024 were detailed. KIMMTRAK sales increased, and clinical trials for brenetafusp and other candidates progressed.
Immunocore reported a 36% increase in KIMMTRAK net product revenue, reaching $70.3 million in Q1 2024. The company continues to expand global access and advance clinical trials for its pipeline candidates, including brenetafusp. Net loss for the quarter was $24.4 million, and cash and cash equivalents stood at $832.8 million.
- KIMMTRAK net revenues reached $70.3 million, a 36% increase year-over-year.
- KIMMTRAK was launched in 7 additional countries, expanding global access.
- Phase 1/2 clinical data for brenetafusp in late-line cutaneous melanoma was selected for oral presentation at ASCO 2024.
- First patient randomization in the PRISM-MEL-301 trial is expected in Q2 2024.
Headline financials
Revenue & EPS history
Immunocore · Revenue · Quarterly
$70.5M
Forward guidance
Immunocore anticipates continued progress in its clinical trials and expansion of KIMMTRAK availability.
Tailwinds
- Randomization of first patient in PRISM-MEL-301 expected in Q2 2024.
- Additional clinical data from brenetafusp trials expected throughout 2024.
- IND or CTA submissions for IMC-P115C by mid-2024 and for IMC-T119C in Q4 2024 remain on track.
- Phase 1 clinical trial for IMC-R117C expected to start in the second half of 2024.
- MAD data for IMC-M113V expected to be presented in the second half of 2024.
Headwinds
- Worsening macroeconomic conditions could impact the company's business.
- Potential delays in clinical trials due to patient enrollment or other factors.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Actions by regulatory agencies may affect the initiation, timing, and progress of clinical trials.
- The company's need for and ability to obtain additional funding on favorable terms.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.2%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+8.3%
Q3 2023
Best reaction
-11.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.6% | +0.0% | -2.1% | |
| Q4 2025 | -4.8% | -3.0% | -12.6% | |
| Q3 2025 | -3.2% | +9.7% | +21.5% | |
| Q1 2025 | +6.3% | +5.3% | +32.8% | |
| Q4 2024 | +5.3% | -1.1% | +1.3% | |
| Q3 2024 | +4.0% | +5.0% | -4.5% | |
| Q2 2024 | +0.8% | +1.7% | -9.5% | |
| Q1 2024 | -1.9% | -6.6% | -31.7% | |
| Q4 2023 | -4.6% | -7.2% | -7.7% | |
| Q3 2023 | +8.3% | +4.6% | +15.8% | |
| Q2 2023 | -3.3% | -5.9% | -12.7% | |
| Q1 2023 | -1.5% | +3.2% | -4.6% | |
| Q4 2022 | -4.9% | -5.1% | -9.9% | |
| Q3 2022 | +2.9% | +13.7% | +9.3% | |
| Q2 2022 | +1.6% | +5.8% | -13.5% | |
| Q1 2022 | -11.0% | +2.7% | +1.4% | |
| Q4 2021 | -0.7% | +7.5% | +37.7% | |
| Q3 2021 | +0.4% | -0.2% | -21.3% | |
| Q2 2021 | -4.9% | -9.5% | -1.4% | |
| Q1 2021 | -1.5% | -9.4% | -5.3% | |
| Q4 2020 | +0.1% | +6.8% | -7.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro